Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Essen Biotech
University of California, Davis
Hadassah Medical Organization
Vall d'Hebron Institute of Oncology
Essen Biotech
H. Lee Moffitt Cancer Center and Research Institute
BGI, China
Second Affiliated Hospital of Soochow University
University of California, Davis
Roger Williams Medical Center